用于皮肤黑色素瘤预后及免疫检查点阻断反应预测的免疫生物标志物
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.
作者信息
Jacquelot Nicolas, Pitt Jonathan M, Enot David P, Roberti Maria Paula, Duong Connie P M, Rusakiewicz Sylvie, Eggermont Alexander M, Zitvogel Laurence
机构信息
Gustave Roussy, Université Paris-Saclay, INSERM U1015, Villejuif, F-94805, France.
Gustave Roussy, Université Paris-saclay, Metabolomics and Cell Biology Platforms, Villejuif, F-94805, France.
出版信息
Oncoimmunology. 2017 Mar 7;6(8):e1299303. doi: 10.1080/2162402X.2017.1299303. eCollection 2017.
Abstract
Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies and the discovery of new immune populations with different prognostic values allow the immune network in the tumor to be better understood. Importantly, new molecules identified and expressed by immune cells have been shown to reduce the antitumor immune efficacy of therapies, prompting researchers to develop antibodies targeting these so-called "immune checkpoints", which have now entered the oncotherapeutic armamentarium.
摘要
现有的临床、解剖病理学和分子生物标志物无法可靠地预测皮肤黑色素瘤的预后。因此需要能够确定哪些患者适合接受辅助治疗的生物标志物。新技术的出现以及具有不同预后价值的新免疫群体的发现，使人们能够更好地了解肿瘤中的免疫网络。重要的是，免疫细胞识别并表达的新分子已被证明会降低治疗的抗肿瘤免疫疗效，促使研究人员开发针对这些所谓“免疫检查点”的抗体，这些抗体现已进入肿瘤治疗药物库。
相似文献
1
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.用于皮肤黑色素瘤预后及免疫检查点阻断反应预测的免疫生物标志物
Oncoimmunology. 2017 Mar 7;6(8):e1299303. doi: 10.1080/2162402X.2017.1299303. eCollection 2017.
2
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma.皮肤黑色素瘤联合免疫治疗试验中的免疫调节单克隆抗体
Front Immunol. 2017 Aug 25;8:1024. doi: 10.3389/fimmu.2017.01024. eCollection 2017.
3
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.程序性细胞死亡蛋白1或联合程序性死亡蛋白1/细胞毒性T淋巴细胞相关抗原4抑制治疗转移性葡萄膜黑色素瘤的预后因素及结局
Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.
4
Biomarkers in melanoma.黑色素瘤中的生物标志物。
Scand J Clin Lab Invest Suppl. 2016;245:S104-12. doi: 10.1080/00365513.2016.1210336. Epub 2016 Jul 28.
5
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
6
Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.全面分析黑色素瘤中肿瘤坏死因子受体 TNFRSF9（4-1BB）的 DNA 甲基化与分子及临床病理特征、免疫浸润以及免疫治疗反应预测的关系。
EBioMedicine. 2020 Feb;52:102647. doi: 10.1016/j.ebiom.2020.102647. Epub 2020 Feb 3.
7
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.对纵向肿瘤样本中的免疫特征进行分析，有助于深入了解免疫检查点阻断反应的生物标志物和耐药机制。
Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.
8
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.免疫检查点单药疗法的临床前疗效并未重现胶质母细胞瘤中基于相应生物标志物的临床预测结果。
Oncoimmunology. 2017 Mar 3;6(4):e1295903. doi: 10.1080/2162402X.2017.1295903. eCollection 2017.
9
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.一种基于全血 RNA 转录本的基因特征与接受检查点抑制剂替西木单抗治疗的晚期黑色素瘤患者 CTLA-4 阻断相关腹泻的发展相关。
J Immunother Cancer. 2018 Sep 18;6(1):90. doi: 10.1186/s40425-018-0408-9.
10
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.PD-1/PD-L1 检查点阻断免疫疗法中的预测生物标志物。
Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10.
引用本文的文献
1
T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma.实体儿科肿瘤微环境中的T细胞：以神经母细胞瘤为例。
Front Immunol. 2025 Feb 28;16:1544137. doi: 10.3389/fimmu.2025.1544137. eCollection 2025.
2
Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.黑色素瘤中的肿瘤浸润淋巴细胞：从预后评估到治疗应用
Front Immunol. 2024 Dec 6;15:1497522. doi: 10.3389/fimmu.2024.1497522. eCollection 2024.
3
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.固有淋巴细胞亚群浸润黑色素瘤和上皮性卵巢肿瘤的特征。
Oncoimmunology. 2024 May 10;13(1):2349347. doi: 10.1080/2162402X.2024.2349347. eCollection 2024.
4
Elevated levels of neutrophil related chemokine citrullinated histone H3, interleukin-8 and C-reaction protein in patients with immune checkpoint inhibitor therapy: predictive biomarkers for response to treatment.免疫检查点抑制剂治疗患者中性粒细胞相关趋化因子瓜氨酸化组蛋白H3、白细胞介素-8和C反应蛋白水平升高：治疗反应的预测生物标志物
Cancer Cell Int. 2023 Aug 14;23(1):167. doi: 10.1186/s12935-023-02994-8.
5
B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis.通过生物信息学分析，B细胞受体信号通路突变作为肺腺癌中免疫检查点抑制剂预后预测指标
J Inflamm Res. 2022 Sep 23;15:5541-5555. doi: 10.2147/JIR.S379016. eCollection 2022.
6
CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma.肿瘤相关巨噬细胞的CCL20/TNF/VEGFA细胞因子分泌表型是皮肤黑色素瘤的不良预后因素。
Cancers (Basel). 2021 Aug 5;13(16):3943. doi: 10.3390/cancers13163943.
7
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.阻断共抑制分子 PD-1 可释放 ILC2 依赖性抗肿瘤免疫应答于黑色素瘤。
Nat Immunol. 2021 Jul;22(7):851-864. doi: 10.1038/s41590-021-00943-z. Epub 2021 Jun 7.
8
Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets.神经母细胞瘤中免疫基因和免疫相关长链非编码RNA的预后特征：基于GEO和TARGET数据集的研究
Front Oncol. 2021 Mar 9;11:631546. doi: 10.3389/fonc.2021.631546. eCollection 2021.
9
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.肿瘤浸润肥大细胞与抗 PD-1 治疗耐药相关。
Nat Commun. 2021 Jan 12;12(1):346. doi: 10.1038/s41467-020-20600-7.
10
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.肿瘤浸润淋巴细胞及其在皮肤黑色素瘤中的预后价值。
Front Immunol. 2020 Sep 10;11:2105. doi: 10.3389/fimmu.2020.02105. eCollection 2020.
本文引用的文献
1
NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.转移性黑色素瘤患者中的NKp30异构体和NKp46转录本：罕见的病情进展良好的黑色素瘤患者中独特的NKp30模式
Oncoimmunology. 2016 Mar 10;5(12):e1154251. doi: 10.1080/2162402X.2016.1154251. eCollection 2016.
2
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.肿瘤干扰素信号传导调控针对免疫检查点阻断的多基因抗性程序。
Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022.
3
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.程序性死亡蛋白1（PD-1）检查点通路的分子与生化方面
N Engl J Med. 2016 Nov 3;375(18):1767-1778. doi: 10.1056/NEJMra1514296.
4
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.伊匹单抗辅助治疗Ⅲ期黑色素瘤的长期生存
N Engl J Med. 2016 Nov 10;375(19):1845-1855. doi: 10.1056/NEJMoa1611299. Epub 2016 Oct 7.
5
Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.原发性黑色素瘤中肿瘤浸润淋巴细胞组成的免疫异质性。
Hum Pathol. 2016 Nov;57:116-125. doi: 10.1016/j.humpath.2016.07.008. Epub 2016 Jul 26.
6
Predictive immune markers in advanced melanoma patients treated with ipilimumab.接受伊匹单抗治疗的晚期黑色素瘤患者的预测性免疫标志物。
Oncoimmunology. 2016 Apr 29;5(6):e1158901. doi: 10.1080/2162402X.2016.1158901. eCollection 2016 Jun.
7
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.与黑色素瘤中PD-1阻断获得性耐药相关的突变
N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.
8
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.血源Vδ1+和Vδ2+ T细胞的比例与接受伊匹单抗治疗的黑色素瘤患者的总生存期相关。
Eur J Cancer. 2016 Sep;64:116-26. doi: 10.1016/j.ejca.2016.06.001. Epub 2016 Jul 9.
9
Natural killer cell memory in context.自然杀伤细胞记忆的相关背景
Semin Immunol. 2016 Aug;28(4):368-76. doi: 10.1016/j.smim.2016.05.008. Epub 2016 Jun 25.
10
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.实体瘤中的免疫检查点抑制剂联合疗法：机遇与挑战
Immunotherapy. 2016 Jun;8(7):821-37. doi: 10.2217/imt-2016-0002.
Zotero 插件